Scarlet fever(SF)is a common communicable disease that results from group A Streptococcus(GAS)infections[1].SF accounted for the global loss of life among children 5–15 years of age in the 18th and 19th centuries[2]....Scarlet fever(SF)is a common communicable disease that results from group A Streptococcus(GAS)infections[1].SF accounted for the global loss of life among children 5–15 years of age in the 18th and 19th centuries[2].A rapid reduction in SF morbidity and mortality occurred due to the scale-up of effective antibiotics and improvements in sanitation and nutrition[3].The unexpected increase in the incidence of SF has attracted a renewed interest in infectious diseases[3].Because the triggers that cause SF outbreaks are not fully understood and there is a scarcity of available vaccines protecting susceptible populations from GAS infections,effective prevention and control plans are required to stop the continued spread of SF.展开更多
1文献来源Conroy T,Hammel P,Hebbar M,et al.FOLFIRINOX or Gemcitabin as adjuvant therapy for pancreatic cancer[J].N Eng J Med,2018,379(25):2395-2406.2证据水平1b。3背景胰腺癌单纯手术治疗的5年生存率较低,即使接受了吉西他...1文献来源Conroy T,Hammel P,Hebbar M,et al.FOLFIRINOX or Gemcitabin as adjuvant therapy for pancreatic cancer[J].N Eng J Med,2018,379(25):2395-2406.2证据水平1b。3背景胰腺癌单纯手术治疗的5年生存率较低,即使接受了吉西他滨或者氟尿嘧啶辅助治疗,仍有大约70%的患者会在2年内出现转移复发[1 2]。因此,探索新的胰腺癌辅助治疗策略具有十分重要的临床意义。作为转移性胰腺癌的一线治疗,与吉西他滨单药化疗相比,FOLFIRINOX方案(持续泵注5 氟尿嘧啶+亚叶酸钙+伊立替康+奥沙利铂)明显延长了患者的总生存期(overall survival,OS)[3]。但FOLFIRINOX方案作为胰腺癌切除术后辅助治疗的价值尚不明确。展开更多
基金supported by the Natural Science Foundation of Henan,ChinaInnovation and Entrepreneurship Training Project for University Students of Henan Province and Xinxiang Medical University[222300420265,S202110472047,S202010472007,and XYXSKYZ201932]the Key Scientific Research Project of Universities in Henan[21A330004]
文摘Scarlet fever(SF)is a common communicable disease that results from group A Streptococcus(GAS)infections[1].SF accounted for the global loss of life among children 5–15 years of age in the 18th and 19th centuries[2].A rapid reduction in SF morbidity and mortality occurred due to the scale-up of effective antibiotics and improvements in sanitation and nutrition[3].The unexpected increase in the incidence of SF has attracted a renewed interest in infectious diseases[3].Because the triggers that cause SF outbreaks are not fully understood and there is a scarcity of available vaccines protecting susceptible populations from GAS infections,effective prevention and control plans are required to stop the continued spread of SF.
文摘1文献来源Conroy T,Hammel P,Hebbar M,et al.FOLFIRINOX or Gemcitabin as adjuvant therapy for pancreatic cancer[J].N Eng J Med,2018,379(25):2395-2406.2证据水平1b。3背景胰腺癌单纯手术治疗的5年生存率较低,即使接受了吉西他滨或者氟尿嘧啶辅助治疗,仍有大约70%的患者会在2年内出现转移复发[1 2]。因此,探索新的胰腺癌辅助治疗策略具有十分重要的临床意义。作为转移性胰腺癌的一线治疗,与吉西他滨单药化疗相比,FOLFIRINOX方案(持续泵注5 氟尿嘧啶+亚叶酸钙+伊立替康+奥沙利铂)明显延长了患者的总生存期(overall survival,OS)[3]。但FOLFIRINOX方案作为胰腺癌切除术后辅助治疗的价值尚不明确。
